Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized vs IV Furosemide in Premature Infants with BPD
NCT03946891Phase 1Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Jun 2016
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of furosemide in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Daily percent change from pre-treatment FiO2 requirement. Planned start Jun 2016; status: withdrawn.
02
Drugs
furosemide
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT03946891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946891.